Abstract: SA-PO0654
Comparative Efficacy of Nefecon vs. Telitacicept in IgAN: A Six-Month Retrospective Cohort Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Fang, Jingyun, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
- Dong, Rong, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
- Yuan, Jing, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
- Zha, Yan, Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
Background
IgA nephropathy (IgAN) is a chronic kidney disease characterized by Gd-IgA1–containing immune complexes. Nefecon (targeting gut mucosal immunity) and telitacicept (targeting aberrant B-cell activation) act via distinct mechanisms, yet real-world head-to-head data are limited. This study compared their 6-month efficacy in IgAN.
Methods
From Jan 2021 to Sep 2025, 25 patients with biopsy-confirmed primary IgAN who received either Nefecon 16 mg/day or telitacicept 160 mg/week were included in this retrospective study. Both groups had optimized supportive care and no additional immunosuppressants. Endpoints were changes in estimated glomerular filtration rate (eGFR) and 24-hour proteinuria, analyzed within and between groups.
Results
Of the 25 patients, 14 received Nefecon and 11 received telitacicept. Baseline characteristics were comparable between groups. After 6 months of treatment, the median eGFR in Nefecon group increased from 47.0 to 53.5 mL/min/1.73m^2 (P<0.001), the median 24-hour proteinuria decreased from1.42 to 0.70g/day (P<0.001). In the telitacicept group, the median eGFR remained stable (56.0 vs 56.0 mL/min/1.73m^2; P=0.301), while the median 24-hour proteinuria decreased from 1.77 to 1.23 g/day (P=0.004). Intergroup comparison showed that Nefecon was associated with a more pronounced benefit in renal function improvement (P<0.001), whereas the efficacy in proteinuria was comparable between groups (P=0.427).
Conclusion
Nefecon demonstrated promising antiproteinuric and renal benefits in patients with IgAN. A potential advantage in renal function improvement compared with telitacicept was observed, which warrants further investigation. The effect of telitacicept on proteinuria observed in this study is somewhat different from that reported in some other studies, which may be related to the smaller dose.